Abstract: Systems and methods for managing patient information across various electronic medical record (EMR) systems, according to some examples can involve providing a patient information management system having a cloud-based application server including a database, a client application interface and a mobile security token. A one-time verification code can be sent from the cloud-based application server to the client computing device and read using the mobile security token. The mobile security token can be matched to a patient demographic record in the database to authenticate the patient using the linked mobile security token.

Abstract: Systems and methods for managing patient information across various electronic medical record (EMR) systems, according to some examples can involve providing a patient information management system having a cloud-based application server including a database, a client application interface and a mobile security token. A one-time verification code can be sent from the cloud-based application server to the client computing device and read using the mobile security token. The mobile security token can be matched to a patient demographic record in the database to authenticate the patient using the linked mobile security token.

Abstract: Gly-Pro-Glu (GPE) is rapidly metabolized in vivo. We found that GPE infusion elicits potent and consistent neuroprotection in all brain regions examined, and in certain embodiments, the effects were greater than those of a bolus injection followed by infusion (“loading dose/infusion”). GPE reduced apoptosis in the hippocampus and inhibited microglial proliferation and prevented the injury-induced loss of astrocytes and improved long-term somatofunction. GPE after infusion showed a broad effective dose range (0.3-30 mg/kg/h) and had a surprisingly extended window of treatment efficacy, permitting its use from 1 to at least as late as 24 h after neural injury. We also found that neuroprotective effects of acute GPE administration were prolonged and therefore capable of being used effectively to treat a variety of neurodegenerative conditions, even when administered after a neural injury.

Abstract: GPE antibodies recognize GPE with high specificity. When used in a radioimmunoassay, they reliably measure the concentration of GPE. They may be used to extend the half-life of GPE both in vivo and in vitro, and in methods of purifying the GPE receptor. Two methods of rpHPLC accurately revolve GPE on the basis of its hydrophobicity.

Abstract: Anti-GPE antibodies are provided that can be used to detect the presence of GPE in a sample. GPE antibodies can be raised against conjugated GPE to produce antibodies that are specific for a GPE that has been derivatized using a similar coupling chemistry as was used for making the GPE conjugate. To detect GPE in a sample, the sample is exposed to a derivatizing agent to produce a derivatized GPE that is recognized by the anti-GPE antibody. Using similar strategies, antibodies can be raised against other weakly immunogenic molecules (WIMs) that can be the basis for assays and kits for assaying for WIMs.